San Jose, CA – According to filings with the U.S. Securities and Exchange Commission, Da Zen Theranostics is raising $5,486,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Yu-Ping Cheng played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Da Zen Theranostics

We have developed a highly effective anti-cancer drug that we believe will treat many forms of cancer and cancer metastasis more effectively than currently therapy. Our approach to the development and testing of anti-cancer drugs in a clinical trial setting is unique. Our proprietary products and processes enable more effective identification, targeting, and treatment of cancer, regardless of tumor location and type. Our advanced technology allows us to cost-effectively develop new, specific cancer therapies essentially a platform giving us competitive and sustainable advantage to develop better anti-cancer drugs more quickly and safely.

To learn more about Da Zen Theranostics, visit http://www.dazenthera.com/

Contact:
Yu-Ping Cheng, Chief Executive Officer
408-489-9383
https://www.linkedin.com/in/yu-ping-cheng-42197213a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved